MRK Jul 2020 87.500 put

OPR - OPR Delayed price. Currency in USD
8.75
0.00 (0.00%)
As of 1:10PM EST. Market open.
Stock chart is not supported by your current browser
Previous close8.75
Open8.75
Bid9.25
Ask9.45
Strike87.50
Expiry date2020-07-17
Day's range8.75 - 8.75
Contract rangeN/A
Volume11
Open interest235
  • Coronavirus fears sparks market swings
    Yahoo Finance Video

    Coronavirus fears sparks market swings

    Yahoo Finance's Anjalee Khemlani outlines market risk as coronavirus fears continue to spook investors.

  • Peter Thiel’s Palantir Wins Role in $823 Million Government Contract
    Bloomberg

    Peter Thiel’s Palantir Wins Role in $823 Million Government Contract

    (Bloomberg) -- Palantir Technologies Inc. scored another win in Washington Tuesday, securing a contract worth as much as $823 million to provide software to the Department of Defense, according to communications reviewed by Bloomberg.The four-year deal represents more than a decade of work by the Palo Alto, California-based data mining startup to break into the club of existing defense contractors, and bolsters the company’s prospects as it prepares it to go public.The contract is the second half of a larger project. Palantir and Raytheon Co. won the first half of the deal in 2018, worth $876 million. This second part involves Palantir working with BAE Systems to replace the U.S. Army’s Distributed Common Ground System, used for aggregating and analyzing data, which has faced technical challenges. Palantir sued the Army in 2016 to win the right to compete for the new contract after the U.S. Government Accountability Office determined the old system was underperforming and over budget. It is unclear how revenue from the contract will be split between Palantir and BAE Systems. The deal will increase annual sales at Palantir’s government division from its current $500 million or so, according to people familiar with Palantir’s finances who asked not to be identified discussing private information. Investor Peter Thiel co-founded Palantir in 2004, and the company’s software has been used for controversial ends like enabling the immigration deportation policies championed by President Trump, as well as for philanthropic ones like preventing sex trafficking and finding missing children.About half of Palantir’s business relies on deals with large corporate customers like Merck KGaA and Airbus SE,  which use the software to manage drug discovery and improve supply chain logistics.The company is exploring both an IPO and a direct listing, but does not yet have a target date for going public, Bloomberg has reported. To contact the author of this story: Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editor responsible for this story: Anne VanderMey at avandermey@bloomberg.net, Alistair BarrFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
    Zacks

    Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

    AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

  • Business Wire

    Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule

    Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Six-Week Dosing Schedule

  • Business Wire

    ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification

    ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification

  • Merck Shares Slip In Favor of a Peer, Evercore ISI Says
    Bloomberg

    Merck Shares Slip In Favor of a Peer, Evercore ISI Says

    (Bloomberg) -- Merck & Co. stock fell to a three-month low on Wednesday after what appeared to be promising data in an aggressive form of breast cancer. But it’s not the data moving shares, Evercore ISI told investors.Instead that as much as 2.5% drop was driven by a rotation away from Merck and into “another large cap pharma name,” Umer Raffat concluded. Evercore declined to comment on which peer it was, saying it was restricted on that stock.That leaves open the door to a number of possibilities as health-care traders pointed to a move away from long investments and toward crowded short names like AbbVie Inc. or Bristol-Myers Squibb Co. Both those companies have more than twice the notional short interest than Merck’s $2.1 billion, according to data from S3 Partners. Evercore suspended coverage on AbbVie last year and has been advising the drugmaker on its deal for Allergan Plc.Technicals could also be spurring the move lower after Merck dropped below its 200-daily moving average Wednesday. The stock has fallen 5.7% since announcing plans for a spinoff last week that analysts warned would only increase its reliance on its top-selling drug Keytruda.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Business Wire

    Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

    Merck’s KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

  • Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

    The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...

  • Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
    Zacks

    Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

    Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

  • Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
    Zacks

    Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

    Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

  • Merck Will No Longer Be ‘Easy to Own’ on Keytruda Dominance
    Bloomberg

    Merck Will No Longer Be ‘Easy to Own’ on Keytruda Dominance

    (Bloomberg) -- Merck & Co.’s plan to spin off its women’s health and biosimilar medicines units is sparking debate about its dependence on its top-selling drug among Wall Street analysts.The move to shed assets will further increase the drugmaker’s reliance on its blockbuster cancer medicine -- Keytruda -- and that’s not sitting well with some. That strategy may fuel a bulls vs bears controversy as Keytruda faces off against lower-priced competition in China and trial results may challenge the medicine’s supremacy in the U.S.A once “easy to own” story introduces a “valuation debate into a well-owned stock,” RBC analyst Randall Stanicky cautioned. “While perhaps unfair, we expect Keytruda concentration to become a bigger theme into competitor data that, while lower-risk, will add questions,” he wrote to clients in a note.Stanicky is one of four of the 20 analysts tracked by Bloomberg who remain neutral on Merck. He trimmed his share price target on the sector perform-rated company to $92 from $99. The company’s stock has dropped over 3% since it announced the spinoff.Even before Merck announced the new set up and ahead of Thursday night’s earnings SVB Leerink analyst Daina Graybosch voiced her concerns about Keytruda drawing political scrutiny during an election year after it overtook Revlimid last year to be the world’s top-selling cancer medicine. Bloomberg compiled sales estimates show Keytruda is on pace to overtake AbbVie Inc.’s Humira as the world’s top-selling medicine in 2023.“Investors have been wary of companies that rely on a single-product,” and Keytruda is set to become half of Merck’s sales by 2027 or 2028, she wrote earlier today.Competitive results -- like those from a kidney cancer drug combination from Bristol-Myers Squibb and Exelixis Inc. expected in the first quarter -- could hurt Keytruda’s dominance if they are able to demonstrate more efficacy, she said. Despite potential Keytruda “roadblocks” Graybosch kept her outperform rating while trimming her share price forecast to $100 from $103 on reimbursement concerns outside the U.S.Morgan Stanley’s David Risinger remained bullish: “Although Keytruda faces competitive threats, we assume that Keytruda’s efficacy bar remains difficult to beat. If there is a novel therapy that outperforms Keytruda some day, that regimen would likely carry additional toxicity...which would likely raise questions about its benefit-risk ratio.”Risinger took down his price target by $4 to $97. The current average price target of $99 implies Merck shares may advance 15% over the next year.(Updates to add chart)\--With assistance from David Tung, Tara Israel and Michael J. Burdette.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Divya Balji, Scott SchnipperFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
    Zacks

    Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

    Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

  • Why Merck (MRK) is a Great Dividend Stock Right Now
    Zacks

    Why Merck (MRK) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • Reuters - UK Focus

    US STOCKS-Wall St gains after strong US data, waning virus fears; Tesla limits Nasdaq's rise

    U.S. stocks rallied for a third straight day on Wednesday on encouraging U.S. economic data and waning fears of the financial fallout from a virus out of China but losses in Tesla shares pulled the Nasdaq off its record high. The ADP National Employment Report showed private payrolls jumped by 291,000 jobs in January, the most since May 2015, while a separate report showed U.S. services sector activity picked up in January, suggesting the economy could continue to grow moderately this year even as consumer spending is slowing. "There is at least not as much of a fear of an outcome of a pandemic that will have as much economic pressure globally as maybe initially was thought,” said Delores Rubin, senior equities trader at Deutsche Bank Wealth Management in New York.

  • Strong Private Sector Payrolls in January
    Zacks

    Strong Private Sector Payrolls in January

    Strong Private Sector Payrolls in January.

  • ADP Posts Blowout +291K New Jobs for January
    Zacks

    ADP Posts Blowout +291K New Jobs for January

    Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.

  • Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
    Zacks

    Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

    Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

  • Merck&Co Earnings Beat, Revenue Misses In Q4
    Investing.com

    Merck&Co Earnings Beat, Revenue Misses In Q4

    Investing.com - Merck&Co; reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

  • Business Wire

    Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results

    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2019.

  • Business Wire

    Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company ("NewCo")

    Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company ("NewCo")

  • Peloton earnings, ADP jobs report: What to know in markets Wednesday
    Yahoo Finance

    Peloton earnings, ADP jobs report: What to know in markets Wednesday

    Private employment data and Peloton earnings will be in focus Wednesday.

  • Day Ahead: Top 3 Things to Watch for Feb. 5
    Investing.com

    Day Ahead: Top 3 Things to Watch for Feb. 5

    Investing.com - Here are three things that could rock the markets tomorrow.

  • Should You Buy Merck (MRK) Ahead of Earnings?
    Zacks

    Should You Buy Merck (MRK) Ahead of Earnings?

    Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more